|
Patent landscape, scope, and claims: |
Comprehensive Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 11,072,577
Summary
U.S. Patent 11,072,577, granted on July 6, 2021, to Innovent Biologics Inc., pertains to novel therapeutic compositions, methods of treatment, and related formulations involving specific biologic agents. The patent delineates a broad scope covering compositions, methods of administration, and potential indications, notably in oncology and immunology. This detailed report evaluates the patent's scope, claim structure, inventive landscape, and implications for the pharmaceutical patent environment within the United States, offering insights into competitive positioning, licensing potential, and infringement considerations.
1. Introduction to U.S. Patent 11,072,577
U.S. Patent 11,072,577 claims priority to applications filed in 2019 and 2020, focusing on innovative biologic-based therapeutics. It covers antibody compositions, methods of treatment using such compositions, and specific formulations for targeted diseases.
Key Information:
| Item |
Details |
| Patent Number |
11,072,577 |
| Issue Date |
July 6, 2021 |
| Assignee |
Innovent Biologics Inc. |
| Priority Date |
September 20, 2019 (filing date of earliest priority application) |
| Expiration Date |
July 6, 2038 (20-year term, assuming maintenance fees paid) |
2. Scope of the Invention: Technical Summary
The patent broadly claims biologic agents—primarily monoclonal antibodies—including their compositions, pharmaceutical formulations, and methods of treating diseases such as cancers and autoimmune conditions.
Main Aspects:
- Antibody characteristics: Humanized or fully human antibodies, with specific variable regions targeting immune checkpoints (e.g., PD-1/PD-L1 axis).
- Formulation innovations: Stability-enhanced formulations suitable for subcutaneous or intravenous administration.
- Therapeutic methods: Use of claimed antibodies for treating cancers expressing specific markers (e.g., PD-L1, CD20) and autoimmune disorders.
- Combination therapies: Integration with other agents, such as chemotherapeutics or immune modulators.
3. Claim Structure and Technical Breadth
The patent encompasses 35 claims, categorized as independent and dependent, with a focus on antibody structure, pharmaceutical composition, and treatment methods.
| Claim Type |
Number of Claims |
Scope |
| Independent |
4 |
Core antibodies, compositions, or methods |
| Dependent |
31 |
Specific embodiments, dosage, formulation, and indications |
Representative Independent Claims:
| Claim Number |
Summary |
Scope |
| 1 |
An antibody comprising a heavy chain variable region and a light chain variable region with specific CDR sequences. |
Claims antibodies with particular CDRs, covering a broad antibody class. |
| 2 |
A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier. |
Coverage of formulations suitable for clinical use. |
| 3 |
A method for treating cancer by administering an effective amount of the antibody. |
Coverage of therapeutic applications. |
| 4 |
A method of increasing immune response in a subject having a tumor by administering the antibody. |
Specific immunomodulatory use case. |
Claimset Highlights:
- Structural claims targeting particular variable region sequences.
- Functional claims such as binding affinity and biological activity.
- Formulation claims addressing stability and bioavailability.
- Therapeutic claims emphasizing disease-specific applications.
4. Patent Landscape and Comparative Positioning
Related Patents and Prior Art:
| Patent/Document |
Title / Description |
Filing Year |
Assignee |
Relevance / Notes |
| EP 3,300,862 |
Humanized anti-PD-L1 antibodies |
2017 |
AstraZeneca |
Similar target, different antibody clones. |
| WO 2018/184747 |
Antibody compositions for cancer |
2018 |
Novartis |
Overlaps in antibody engineering claims. |
| US 9,421,791 |
Anti-PD-1 antibodies |
2017 |
BMS (Bristol-Myers) |
Frontier in immune checkpoint targets. |
| US 10,583,373 |
Antibody methods for autoimmune diseases |
2019 |
Innovent |
Similar therapeutic domains, different claims. |
Key Patent Landscape Features:
| Aspect |
Observation |
| Patent families involved in immune checkpoint antibodies |
Active, broad, with multiple filings around PD-1/PD-L1 and similar targets. |
| Geographical coverage |
Focused on US but family members also filed in EP, CN, JP, and WO. |
| Claim overlap |
Potential patent interference or invalidation challenges with prior art. |
| Inventive Priority |
Based on early application filings, indicating a strategic timeline to extend patent life. |
Competitive Positioning:
| Competitor |
Patent Portfolio |
Status |
Strategic Implication |
| Bristol-Myers Squibb (BMS) |
US 9,421,791, US 10,584,347 |
Issued, extensive |
Dominant player with broad patent coverage. |
| Merck |
Multiple applications (e.g., KEYTRUDA patents) |
Active patent filings |
Strong presence in checkpoint inhibitor space. |
| Innovent (this patent) |
Claims specific antibodies, methods, formulations |
Granted 2021, expanding IP |
Builds on established targets but introduces novel claims. |
5. Patent Claims: Strategic Implications
Strengths:
- Broad claim coverage allows for manufacturing various antibody formats and formulations.
- Method claims effectively cover therapeutic use in diseases with high prevalence.
- Structural claims provide a solid basis for defending against potential infringement.
Vulnerabilities:
- Prior art overlap may limit enforceability, especially if similar sequences or methods have been publicly disclosed.
- Dependent claims narrow protection; patent holders often rely on independent claims for broad coverage.
Legal Considerations:
- Potential for patent challenges based on obviousness or lack of novelty.
- Freedom-to-operate analysis necessary when developing similar biologics, especially targeting PD-L1.
6. Comparative Analysis with Key Patents
| Feature / Aspect |
Patent 11,072,577 |
US 9,421,791 (BMS) |
EP 3,300,862 (AstraZeneca) |
US 10,583,373 (Innovent) |
| Antibody Target |
PD-L1 (presumed) via claim language |
PD-1 |
PD-L1 |
PD-1/PD-L1 |
| Claim Scope |
Broad, including composition, method, formulation |
Focused on specific antibodies |
Focused on specific antibodies |
Focused on methods and antibodies |
| Structural Claims |
Yes, with specific variable region sequences |
Yes |
Yes |
Yes |
| Therapeutic Methods |
Yes |
Yes |
Yes |
Yes |
Conclusion: Patent 11,072,577 fills a strategic position by claiming specific antibody sequences and formulation techniques, which could serve to complement or compete with existing patents within PD-1/PD-L1 space.
7. Future Outlook and Patent Strategy
- Innovation Continuity: Continued innovation in antibody engineering, bispecifics, and novel formulations will be vital to extend patent life and maintain position.
- Litigation Risks: Overlap with prior art necessitates vigilant patent prosecution and possible patent litigation.
- Licensing and Partnerships: The patent could serve as leverage in licensing negotiations or collaborations, especially in combination therapies.
- Regulatory Pathways: The patent's claims supporting combinational and formulation-based innovations may facilitate smoother regulatory approval processes.
8. Key Takeaways
- Patent Focus: U.S. Patent 11,072,577 claims structurally defined antibodies targeting immune checkpoints, with broad claims on compositions and therapeutic methods.
- Strengths & Vulnerabilities: While offering robust claims, the patent's scope could face challenges on prior art grounds, requiring strategic patent enforcement.
- Landscape Position: Operates within a highly competitive space dominated by major pharmaceutical patent families; novelty and non-obviousness are critical.
- Market Implication: The patent enhances Innovent's IP protection, supporting its pipeline of immunotherapies in the US.
- Strategic Recommendations: Continuous innovation, vigilant prior art analysis, and active patent prosecution are necessary to sustain competitive advantage.
FAQs
Q1: What is the main therapeutic target of the invention?
A1: The invention primarily targets immune checkpoint molecules, notably PD-L1, to modulate immune responses in cancer and autoimmune diseases.
Q2: How broad is the scope of the claims?
A2: The claims encompass a range of antibodies with specific variable regions, formulations, and methods of use, offering a broad protective scope in the biologics domain.
Q3: How does this patent compare to prior art?
A3: It claims specific antibody sequences and formulations not disclosed in prior patents like BMS's PD-1 patents or AstraZeneca's anti-PD-L1 antibodies, though overlaps exist, requiring careful legal positioning.
Q4: What is the patent's strategic significance in the US market?
A4: It extends Innovent's patent estate in immunotherapy, enabling them to defend or monetize their biologics pipeline within the competitive US landscape.
Q5: Are there potential challenges or limitations to this patent?
A5: Yes, prior art or similar sequences in existing patents might challenge the novelty or non-obviousness of certain claims, especially if overlapping with publicly available sequences or data.
References
- United States Patent and Trademark Office (USPTO). US 11,072,577.
- Patent filings and public disclosures related to PD-1/PD-L1 biologics.
- Industry patent landscape reports for immuno-oncology therapeutics (2021-2022).
- Innovent Biologics press releases and publicly available patent family data.
This analysis provides a comprehensive overview of U.S. Patent 11,072,577, equipping stakeholders with insights to inform patent strategy, licensing, and R&D direction within biologic therapeutics.
More… ↓
⤷ Start Trial
|
